The family of BIOMEX GmbH, Europe’s leading provider of human biospecimens for the diagnostics and life science industry, continues to grow. Since the first of August, provitro AG a renowned expert in target validation with its location in Berlin is part of Mex group.

provitro stands for more than fifteen years of experience in commercialization of cell culture technologies, tissue microarrays and target validation services backed up by scientific cooperation with the Pathological Institute of Charité Universitätsmedizin Berlin.

Dr. Manrico Paulitschke, CEO of provitro AG, stated: “We take pride in delivering not only high-quality products and state-of-the-art services but also tailor-made solutions to meet our customers’ specific needs. Our team’s commitment to driving progress at the interface of research and development has been unwavering. That’s why we are more than excited to leverage our full potential and provide our expertise to a larger audience together with BIOMEX.”

This acquisition is a significant step for both companies as it aligns with their shared values of competence, vision and sustainability. Oliver Bošnjak, General Manager of BIOMEX, emphasized, “The values that underpin the work of provitro AG perfectly complement BIOMEX’s mission of empowering scientists.”

By combining their expertise, BIOMEX aims to reinforce its position in the industry, enabling the company to offer customers an even more comprehensive range of solutions and services.

“We are eagerly looking forward to witnessing the positive impact of this collaboration, and we are confident that the joint knowledge and capabilities of BIOMEX and provitro AG will continue to drive progress in the life science industry,” added Oliver Bošnjak.

This proactive step is a response to the evolving needs of researchers towards enriching the landscape of the life sciences industry. The partnership is an example of a forward-looking approach designed to meet the dynamic needs of researchers by harmonizing shared knowledge and resources.